Filing Flows › Ovid Therapeutics (OVID) › R&D spending
Ovid Therapeutics (OVID) R&D spending by quarter
Ovid Therapeutics' R&D spending was $10.0M in Q2 2026 (second quarter 2026), +51% from Q4 2025. Over the last 6 quarters it ranged from $5.9M (Q3 2025) to $10.0M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $10.0M | +51% | +54% |
| Q4 2025 | $6.6M | +12% | +11% |
| Q3 2025 | $5.9M | -9% | — |
| Q2 2025 | $6.5M | -3% | — |
| Q1 2025 | $6.7M | +12% | — |
| Q4 2024 | $5.9M | — | — |
Q2 2026 at a glance
Ovid Therapeutics, Q2 2026: revenue $733K (-88% year over year), net loss $15.0M, operating cash flow −$17.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is Ovid Therapeutics' R&D spending?
Ovid Therapeutics' R&D spending was $10.0M in Q2 2026 (second quarter 2026), +51% from Q4 2025.
How has Ovid Therapeutics' R&D spending changed?
Over the last 6 quarters it ranged from $5.9M (Q3 2025) to $10.0M (Q2 2026).